<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Ophthalmic Vis Res</journal-id><journal-id journal-id-type="iso-abbrev">J Ophthalmic Vis Res</journal-id><journal-id journal-id-type="publisher-id">JOVR</journal-id><journal-title-group><journal-title>Journal of Ophthalmic &#x00026; Vision Research</journal-title></journal-title-group><issn pub-type="ppub">2008-2010</issn><issn pub-type="epub">2008-322X</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26425312</article-id><article-id pub-id-type="pmc">4568607</article-id><article-id pub-id-type="publisher-id">JOVR-10-118</article-id><article-id pub-id-type="doi">10.4103/2008-322X.163776</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Lens Densitometry after Corneal Cross-linking in Patients with Keratoconus Using a Scheimpflug Camera</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Baradaran-Rafii</surname><given-names>Alireza</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Amiri</surname><given-names>Mohammad Aghazazeh</given-names></name><degrees>OD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mohaghegh</surname><given-names>Sahar</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Zarei-Ghanavati</surname><given-names>Mehran</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label><italic>Ocular Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran</italic></aff><aff id="aff2"><label>2</label><italic>Department of Optometry, Shahid Beheshti University of Medical Sciences, Tehran, Iran</italic></aff><aff id="aff3"><label>3</label><italic>Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran</italic></aff><aff id="aff4"><label>4</label><italic>Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran</italic></aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Sahar Mohaghegh, MS. Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, No. 23, Paidarfard Street, Boostan 9 Street, Pasdaran Avenue, Tehran 16666, Iran. E-mail: <email xlink:href="mohaghegh_sahar@yahoo.com">mohaghegh_sahar@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Apr-Jun</season><year>2015</year></pub-date><volume>10</volume><issue>2</issue><fpage>118</fpage><lpage>122</lpage><history><date date-type="received"><day>07</day><month>10</month><year>2013</year></date><date date-type="accepted"><day>14</day><month>6</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Journal of Ophthalmic and Vision Research</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Purpose:</title><p>To evaluate changes in crystalline lens densitometry following corneal cross-linking (CXL) in keratoconic patients.</p></sec><sec id="st2"><title>Methods:</title><p>In a quasi-experimental study, three-dimensional lens densitometry was performed using the Pentacam Scheimpflug camera (Oculus Optikgerate GmbH, Wetzlar, Germany) at baseline and six months after CXL. Densitometry was performed in a fixed area of 2 inch &#x000d7; 1 inch of the anterior capsule and anterior lens cortex. The subject group included patients with progressive keratoconus who underwent CXL (<italic>n</italic> = 40) and the control group was comprised of aged-matched patients with non-progressive keratoconus (<italic>n</italic> = 36).</p></sec><sec id="st3"><title>Results:</title><p>Mean age of the case and control groups was 25.8 &#x000b1; 4.0 and 25.0 &#x000b1; 4.1 years, respectively (<italic>P</italic> = 0.392). Mean lens density in the CXL group was 6.68% &#x000b1; 0.58% at baseline and 6.77% &#x000b1; 0.53% at the last visit (<italic>P</italic> = 0.352). Corresponding figures in the control group were 6.53% &#x000b1; 0.27% and 6.39% &#x000b1; 0.31%, respectively (<italic>P</italic> = 0.213). There was no significant difference between the study groups at baseline or six months later (<italic>P</italic> = 0.96).</p></sec><sec id="st4"><title>Conclusion:</title><p>In this short term study with six months&#x02019; follow-up, we observed no significant impact on lens density following exposure of the crystalline lens to ultraviolet A and riboflavin free radicals in the CXL procedure.</p></sec></abstract><kwd-group><kwd>Corneal Cross-linking</kwd><kwd>Free Radicals</kwd><kwd>Lens Clarity</kwd><kwd>Scheimpflug Camera</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Collagen cross-linking (CXL) is a corneal tissue strengthening technique that halts the progression of keratoconus[<xref rid="ref1" ref-type="bibr">1</xref>] and corneal ectasia following laser <italic>in situ</italic> keratomileusis (LASIK).[<xref rid="ref2" ref-type="bibr">2</xref>] It has also been used in poor candidates for laser refractive surgery,[<xref rid="ref3" ref-type="bibr">3</xref>] in corneal melting processes,[<xref rid="ref4" ref-type="bibr">4</xref>] pellucid marginal degeneration,[<xref rid="ref5" ref-type="bibr">5</xref>] corneal edema,[<xref rid="ref6" ref-type="bibr">6</xref>] bullous keratopathy,[<xref rid="ref7" ref-type="bibr">7</xref>] <italic>in vitro</italic> fungal keratitis[<xref rid="ref8" ref-type="bibr">8</xref>] and infectious keratitis not responding to treatment.[<xref rid="ref9" ref-type="bibr">9</xref>] Ultraviolet A (UVA) irradiation (370 nm wavelength) and a photosensitizer, i.e., riboflavin, are used during the CXL procedure.[<xref rid="ref2" ref-type="bibr">2</xref>]</p><p>The mechanism of CXL is not entirely understood. Following riboflavin exposure to UVA, these molecules are excited into a triplet state, thereby generating reactive oxygen species. Current thinking is that interaction of reactive oxygen with available groups nearby leads to formation of additional covalent bonds between collagen molecules in the cornea.[<xref rid="ref10" ref-type="bibr">10</xref>] The consequence of these biomechanical reactions is stiffening of the corneal tissue.[<xref rid="ref10" ref-type="bibr">10</xref>]</p><p>Oxidative stress is apparent in pathologies associated with many aging diseases including atherosclerosis, diabetes mellitus, rheumatoid arthritis and neurodegenerative diseases.[<xref rid="ref11" ref-type="bibr">11</xref>] UV irradiation is one of the most important factors for inducing oxidative stress. The role of UVA irradiation in the pathogenesis of several eye diseases including pinguecula, pterygium, cataracts, glaucoma and retinopathies has been demonstrated.[<xref rid="ref12" ref-type="bibr">12</xref>] Epidemiological studies have indicated that UV radiation is one of the primary factors leading to senile cataract formation.[<xref rid="ref13" ref-type="bibr">13</xref>] The strongest hypothesis regarding the cataractogenic effect of UVA concerns photochemical generation of reactive oxygen species in the aqueous and lens.[<xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref>]</p><p>During CXL, the eye and its important visual elements including the lens and retina are exposed to UVA irradiation. Although riboflavin acts as a photo-blocker and an insignificant amount of UVA directly reaches inner ocular tissues,[<xref rid="ref17" ref-type="bibr">17</xref>] it generates reactive oxygen species (free radicals) following UVA exposure that can cause cell damage. By diffusion through the cornea, free radicals may enter the anterior chamber and in this way come in contact with the crystalline lens.</p><p>Diffusion of free radicals may theoretically lead to adverse effects including endothelial damage and alteration in crystalline lens clarity. The detrimental effects of UVA irradiation on the corneal endothelium, especially in eyes with thin cornea (less than 400 &#x000b5;m), has already been established.[<xref rid="ref18" ref-type="bibr">18</xref>] Recently, there have been reports of endothelial damage after standard CXL procedures (corneal thickness &#x0003e;400 &#x000b5;m).[<xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref20" ref-type="bibr">20</xref>] To the best of our knowledge, there are no reports on the cataractogenic effect of UVA irradiation during CXL procedures. In two previous studies, it has been shown that there are no lens density changes following CXL treatment.[<xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref22" ref-type="bibr">22</xref>] Considering safety issues involved in CXL, more studies are needed in this area. The purpose of the current study was to evaluate changes in lens density six months after CXL using a Scheimpflug camera.</p></sec><sec sec-type="methods" id="sec1-2"><title>METHODS</title><sec id="sec2-1"><title>Study Participiants</title><p>This quasi-experimental study was conducted at Labbafinejad Medical Center, Shahid Beheshti Medical University, Tehran, Iran, from January 2012 to July 2012. Forty eyes of 25 patients and 36 eyes of 18 aged-matched patients were included in the subject and control groups, respectively. All potential patients with keratoconus had been regularly followed-up in the cornea clinic. During each visit, a complete eye examination including uncorrected visual acuity (UCVA) and best spectacle-corrected visual acuity (BSCVA) measurements, as well as refraction and topography (Orbscan IIz, Bausch and Lomb, Rochester, NY, USA) were performed. Patients with progressive keratoconus and no evidence of corneal scarring were included in the subject group for CXL surgery, while patients with non-progressive keratoconus were included in the control group.</p><p>On topography, progression of keratoconus was defined as 1 diopter increase in maximum keratometry or at least a 50 &#x000b5;m decrease in corneal thickness over one year. Ultrasonic pachymetry (Nidek UP-1000, Nidek. Technologies, Gamagori, Japan) was performed for all patients in the subject group prior to CXL. Patients with corneal thickness less than 400 &#x000b5;m at the thinnest point, evidence of crystalline lens opacity, severe dry eye, concurrent corneal infections, pregnancy, concomitant autoimmune diseases, any systemic collagen vascular diseases and prior incisional refractive surgery (radial keratotomy or astigmatic keratotomy) were excluded. All patients provided informed consent after receiving a detailed description of the nature of the treatment.</p></sec><sec id="sec2-2"><title>Corneal Collagen Cross-linking Procedure</title><p>The standard CXL procedure was performed including instillation of topical anesthesia (tetracaine 0.5%) and mechanical epithelial removal from the central 8 mm zone of the cornea with a surgical blade. Prior to UVA irradiation, riboflavin 0.1% solution (10 mg riboflavin in 10 mL dextran 20% solution) was instilled every three minutes for 30 min. Instillation was continued every three minutes for an additional 30 min during irradiation. A UV-X device (IROC, Z&#x000fc;rich, Switzerland) was used to deliver UVA irradiation. The instrument was set at a safe working distance of 5 cm from the corneal surface with a medium size aperture at a wavelength of 370 nm and surface irradiance of 3 mW/cm<sup>2</sup>. A calibrated UVA meter (LaserMate-Q, LASER 2000, Wessling, Germany) was used to control the desired levels of irradiance prior to each treatment.</p><p>After treatment, the patient received topical ciprofloxacin 0.3% and betamethasone 0.1% with an extended-wear night and day bandage contact lens (CIBA Vision). Antibiotic drops, four times daily, were continued until complete re-epithelialization of the cornea. Steroid drops, twice daily, were continued for one month.</p></sec><sec id="sec2-3"><title>Scheimpflug Imaging</title><p>The Scheimpflug camera (Pentacam, Oculus Optikgerate GmbH, Wetzlar, Germany) is a non-invasive diagnostic system designed for analyzing the anterior segment of the eye. The device collects 25,000 elevation data points that are processed to generate a three-dimensional representation of the anterior segment and crystalline lens. The camera rotates around the eye from 0 to 180 degrees and captures 25 single slit images in fewer than two seconds. The Pentacam can also be used as an objective method for the evaluation of crystalline lens density. Using the individual images, the program quantifies lens density on a scale of 0-100 (0 = no cloudiness; 100 = completely opaque lens). In addition, to determining point and linear density, the system provides three-dimensional density evaluation for a specific area drawn on the Scheimpflug image. Means density, maximum density and standard deviation in a specific area can be calculated.</p><p>For all patients, lens densitometry was performed in a room with dim illumination. The patient was seated with their chin on a chinrest and forehead against the forehead strap and asked to fixate their eyes ahead on a target. To reduce operator dependent variables, the Pentacam automatic release mode was used. In this mode, the instrument automatically determines when correct focus and alignment with the corneal apex have been achieved, and then performs a scan. The pupil was dilated 30 min prior to each Pentacam examination (at baseline and after six months) using tropicamide drops instilled twice, five minutes apart. The density threshold was set to 20%. Three-dimensional lens density of the anterior capsule and anterior cortex in a fixed area of 1 &#x000d7; 2 inches was measured in all patients. Lens densitometry was performed on the same segment of the Pentacam image, a segment from 98&#x000b0; to 237&#x000b0;, for all patients. If image quality was poor in this segment, a best image quality segment was chosen instead. The optical axis of the eye, which was marked by the Pentacam device, was considered as a reference point for guaranteeing evaluation of the same area in the second Pentacam examination. The measurement square was set in such a way that the optical axis was located in its middle for each examination [<xref ref-type="fig" rid="F1">Figure 1</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Galilei view of the anterior segment measuring corneal thickness.</p></caption><graphic xlink:href="JOVR-10-118-g001"/></fig></sec><sec id="sec2-4"><title>Statistical Analysis</title><p>An independent paired <italic>t</italic>-test was used for continuous normally distributed variable (lens density). <italic>P</italic> values less than 0.05 were considered as statistically significant. Statistical analysis was performed with SPSS for Windows Software (version 17.0, SPSS, Inc., Chicago, Illinois, USA).</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>Forty eyes of 25 patients, including 17 male and 8 female patients with progressive keratoconus (subjects) and 36 eyes of 18 patients including 10 male and 8 female subjects with non-progressive keratoconus (controls) were evaluated. Mean age of the subject and control groups was 25.8 &#x000b1; 4 (range, 18-30) and 25 &#x000b1; 4.1 (range, 20-30) years, respectively (<italic>P</italic> = 0.392).</p><p>In the subject group, mean lens density was 6.68% &#x000b1; 0.58% (range, 5.50% to 8.20%) at baseline and 6.77% &#x000b1; 0.53% (range, 5.90% to 8.20%) at the last visit (<italic>P</italic> = 0.352). In the control group, mean lens density was 6.53% &#x000b1; 0.27% (range, 6.30% to 7.10%) at baseline and 6.39% &#x000b1; 0.31% (range, 5.90% to 6.80%) at the last visit (<italic>P</italic> = 0.213). There was no statistically significant difference in terms of lens density assessed by Pentacam between the study groups at baseline or six month later (<italic>P</italic> = 0.96).</p></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>Collagen cross-linking is a therapeutic modality for progressive keratoconus and post-LASIK ectasia. As any other new treatment, safety concerns are of great importance. The published literature shows that with CXL, in combination with riboflavin and a minimal corneal thickness of 400 microns, insignificant amounts of UVA irradiance reach inner ocular tissues, including the lens and retina, and there is no evidence of UVA-induced damage in these tissues.[<xref rid="ref17" ref-type="bibr">17</xref>] <italic>In vitro</italic> studies have revealed that with corneal thickness less than 400 microns, endothelial damage due to UV exposure is a possible risk.[<xref rid="ref18" ref-type="bibr">18</xref>] Recently, some reports have raised concerns for corneal endothelial damage after standard CXL procedure.[<xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref20" ref-type="bibr">20</xref>]</p><p>During CXL, riboflavin in conjunction with UVA is excited to the triplet state, inducing reactive oxygen species which by diffusion through the cornea, may enter the anterior chamber and come in contact with the crystalline lens. Several studies have shown that reactive oxygen species accelerate cataract formation.[<xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref>] The cataractogenic effect of excited riboflavin has been revealed <italic>in vitro</italic>.[<xref rid="ref15" ref-type="bibr">15</xref>] A minimal amount of UVA reaching the lens may also theoretically affect crystalline lens transparency. Therefore, the crystalline lens may be prone to cataract formation or changes in density during this procedure.</p><p>In the current study we found that exposure of the crystalline lens to UVA and triplet state of riboflavin during CXL did not significantly impact lens density measured with a Scheimpflug camera. This is in line with the results of two other studies performed by Vinciguerraet al[<xref rid="ref21" ref-type="bibr">21</xref>] and Grewal <italic>et al.</italic>[<xref rid="ref22" ref-type="bibr">22</xref>] Vinciguerra et al studied 12 eyes with a 36-month follow-up and evaluated a 1.2 mm diameter cylindrical-shaped central section of the lens.[<xref rid="ref21" ref-type="bibr">21</xref>] These authors did not find any deterioration of the crystalline lens transparency or permanent negative side-effects on the cornea and endothelium.[<xref rid="ref21" ref-type="bibr">21</xref>] Grewal et al also reported no change in crystalline lens density 12 months after CXL in 102 patients.[<xref rid="ref22" ref-type="bibr">22</xref>] In the current study we evaluated the density of the anterior capsule and anterior cortex of the lens, as these areas are more prone to riboflavin free radicals and UVA irradiation during CXL.</p><p>The Scheimpflug camera technology has been used for objective quantification of crystalline lens density in many research studies and its repeatability and sensitivity to lens change over time has been confirmed.[<xref rid="ref23" ref-type="bibr">23</xref><xref rid="ref24" ref-type="bibr">24</xref>] The repeatability and validity of Pentacam measurements regarding lens densitometry has been confirmed by Kirkwood <italic>et al.</italic>[<xref rid="ref25" ref-type="bibr">25</xref>] The application of Pentacam densitometry for studies on cataracts and cataract prevention has been published in recent studies.[<xref rid="ref26" ref-type="bibr">26</xref>] Although the Scheimpflug camera is sensitive enough to determine lens density changes, a more precise method may be required to detect fine oxidative stress in the crystalline lens during CXL. In previous <italic>in vitro</italic> studies, a decrease in the active transport of ions across the crystalline lens indicates damage,[<xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref>] however, there are limitations to this method where the human eye is concerned.</p><p>There are concerns pertaining to changes in corneal transparency following CXL and its effect on Pentacam accuracy. After CXL, there is a 12.2% increase in the diameter of corneal fibrils.[<xref rid="ref27" ref-type="bibr">27</xref>] To maintain corneal transparency, the collagen fibril diameter should not exceed one third of the wavelength of visible light (150 nm).[<xref rid="ref28" ref-type="bibr">28</xref>] The 12.2% increase in collagen fiber diameter in CXL does not approach this threshold and therefore does not seem to affect corneal transparency.[<xref rid="ref27" ref-type="bibr">27</xref><xref rid="ref28" ref-type="bibr">28</xref>] As such, there should be no concern about alteration in the optical transparency of the cornea after CXL using Pentacam.</p><p>In summary, we observed no signs of cataractogenesis or any change in anterior lens capsule or anterior cortical density following CXL for progressive keratoconus with short term follow-up using the Pentacam. According to <italic>in vitro</italic> studies, although there may be some oxidative stress in the crystalline lens during CXL, it may not be significant enough to be measured by a Scheimpflug camera. Measuring free radical levels in the aqueous humour following CXL treatment and its comparison with free radical levels in the normal eye may better elucidate this matter in later studies.</p><sec id="sec2-5"><title>Financial Support and Sponsorship</title><p>Nil.</p></sec><sec id="sec2-6"><title>Conflicts of Interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ack><title>Acknowledgements</title><p>The authors thank Razi Eye Clinic, Tehran, Iran for their technical assistance.</p></ack><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wollensak</surname><given-names>G</given-names></name><name><surname>Spoerl</surname><given-names>E</given-names></name><name><surname>Seiler</surname><given-names>T</given-names></name></person-group><article-title>Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus</article-title><source>Am J Ophthalmol</source><year>2003</year><volume>135</volume><fpage>620</fpage><lpage>627</lpage><pub-id pub-id-type="pmid">12719068</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Fan</surname><given-names>ZJ</given-names></name><name><surname>Peng</surname><given-names>XJ</given-names></name></person-group><article-title>Corneal collagen crosslinking for corneal ectasia of post-LASIK: One-year results</article-title><source>Int J Ophthalmol</source><year>2012</year><volume>5</volume><fpage>190</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">22762048</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>DT</given-names></name><name><surname>Holland</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>JC</given-names></name><name><surname>Moloney</surname><given-names>G</given-names></name></person-group><article-title>Clinical results of topography-based customized ablations in highly aberrated eyes and keratoconus/ectasia with cross-linking</article-title><source>J Refract Surg</source><year>2012</year><volume>28</volume><fpage>S841</fpage><lpage>S848</lpage><pub-id pub-id-type="pmid">23447899</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Sabai</surname><given-names>N</given-names></name><name><surname>Koppen</surname><given-names>C</given-names></name><name><surname>Tassignon</surname><given-names>MJ</given-names></name></person-group><article-title>UVA/riboflavin crosslinking as treatment for corneal melting</article-title><source>Bull Soc Belge Ophtalmol</source><year>2010</year><volume>315</volume><fpage>13</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">21110504</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spadea</surname><given-names>L</given-names></name></person-group><article-title>Corneal collagen cross-linking with riboflavin and UVA irradiation in pellucid marginal degeneration</article-title><source>J Refract Surg</source><year>2010</year><volume>26</volume><fpage>375</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">20128533</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehlers</surname><given-names>N</given-names></name><name><surname>Hjortdal</surname><given-names>J</given-names></name><name><surname>Nielsen</surname><given-names>K</given-names></name><name><surname>S&#x000f8;ndergaard</surname><given-names>A</given-names></name></person-group><article-title>Riboflavin-UVA treatment in the management of edema and nonhealing ulcers of the cornea</article-title><source>J Refract Surg</source><year>2009</year><volume>25</volume><fpage>S803</fpage><lpage>S806</lpage><pub-id pub-id-type="pmid">19772255</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghanem</surname><given-names>RC</given-names></name><name><surname>Santhiago</surname><given-names>MR</given-names></name><name><surname>Berti</surname><given-names>TB</given-names></name><name><surname>Thomaz</surname><given-names>S</given-names></name><name><surname>Netto</surname><given-names>MV</given-names></name></person-group><article-title>Collagen crosslinking with riboflavin and ultraviolet-A in eyes with pseudophakic bullous keratopathy</article-title><source>J Cataract Refract Surg</source><year>2010</year><volume>36</volume><fpage>273</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">20152609</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galperin</surname><given-names>G</given-names></name><name><surname>Berra</surname><given-names>M</given-names></name><name><surname>Tau</surname><given-names>J</given-names></name><name><surname>Boscaro</surname><given-names>G</given-names></name><name><surname>Zarate</surname><given-names>J</given-names></name><name><surname>Berra</surname><given-names>A</given-names></name></person-group><article-title>Treatment of fungal keratitis from Fusarium infection by corneal cross-linking</article-title><source>Cornea</source><year>2012</year><volume>31</volume><fpage>176</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">22081155</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mor&#x000e9;n</surname><given-names>H</given-names></name><name><surname>Malmsj&#x000f6;</surname><given-names>M</given-names></name><name><surname>Mortensen</surname><given-names>J</given-names></name><name><surname>Ohrstr&#x000f6;m</surname><given-names>A</given-names></name></person-group><article-title>Riboflavin and ultraviolet acollagen crosslinking of the cornea for the treatment of keratitis</article-title><source>Cornea</source><year>2010</year><volume>29</volume><fpage>102</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">19730094</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCall</surname><given-names>AS</given-names></name><name><surname>Kraft</surname><given-names>S</given-names></name><name><surname>Edelhauser</surname><given-names>HF</given-names></name><name><surname>Kidder</surname><given-names>GW</given-names></name><name><surname>Lundquist</surname><given-names>RR</given-names></name><name><surname>Bradshaw</surname><given-names>HE</given-names></name><etal/></person-group><article-title>Mechanisms of corneal tissue cross-linking in response to treatment with topical riboflavin and long-wavelength ultraviolet radiation (UVA)</article-title><source>Invest Ophthalmol Vis Sci</source><year>2010</year><volume>51</volume><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">19643975</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valko</surname><given-names>M</given-names></name><name><surname>Leibfritz</surname><given-names>D</given-names></name><name><surname>Moncol</surname><given-names>J</given-names></name><name><surname>Cronin</surname><given-names>MT</given-names></name><name><surname>Mazur</surname><given-names>M</given-names></name><name><surname>Telser</surname><given-names>J</given-names></name></person-group><article-title>Free radicals and antioxidants in normal physiological functions and human disease</article-title><source>Int J Biochem CellBiol</source><year>2007</year><volume>39</volume><fpage>44</fpage><lpage>84</lpage></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacc&#x000e0;</surname><given-names>SC</given-names></name><name><surname>Roszkowska</surname><given-names>AM</given-names></name><name><surname>Izzotti</surname><given-names>A</given-names></name></person-group><article-title>Environmental light and endogenous antioxidants as the main determinants of non-cancer ocular diseases</article-title><source>Mutat Res</source><year>2013</year><volume>752</volume><fpage>153</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">23337404</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azzam</surname><given-names>N</given-names></name><name><surname>Levanon</surname><given-names>D</given-names></name><name><surname>Dovrat</surname><given-names>A</given-names></name></person-group><article-title>Effects of UV-A irradiation on lens morphology and optics</article-title><source>Exp Gerontol</source><year>2004</year><volume>39</volume><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">14724074</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zigman</surname><given-names>S</given-names></name></person-group><article-title>Lens UVA photobiology</article-title><source>J Ocul Pharmacol Ther</source><year>2000</year><volume>16</volume><fpage>161</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">10803426</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hegde</surname><given-names>KR</given-names></name><name><surname>Kovtun</surname><given-names>S</given-names></name><name><surname>Varma</surname><given-names>SD</given-names></name></person-group><article-title>Induction of ultraviolet cataracts <italic>in vitro</italic>: Prevention by pyruvate</article-title><source>J Ocul Pharmacol Ther</source><year>2007</year><volume>23</volume><fpage>492</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">17900232</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varma</surname><given-names>SD</given-names></name><name><surname>Kovtun</surname><given-names>S</given-names></name><name><surname>Hegde</surname><given-names>KR</given-names></name></person-group><article-title>Role of ultraviolet irradiation and oxidative stress in cataract formation-medical prevention by nutritional antioxidants and metabolic agonists</article-title><source>Eye Contact Lens</source><year>2011</year><volume>37</volume><fpage>233</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">21670697</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spoerl</surname><given-names>E</given-names></name><name><surname>Mrochen</surname><given-names>M</given-names></name><name><surname>Sliney</surname><given-names>D</given-names></name><name><surname>Trokel</surname><given-names>S</given-names></name><name><surname>Seiler</surname><given-names>T</given-names></name></person-group><article-title>Safety of UVA-riboflavin cross-linking of the cornea</article-title><source>Cornea</source><year>2007</year><volume>26</volume><fpage>385</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">17457183</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wollensak</surname><given-names>G</given-names></name><name><surname>Sp&#x000f6;rl</surname><given-names>E</given-names></name><name><surname>Reber</surname><given-names>F</given-names></name><name><surname>Pillunat</surname><given-names>L</given-names></name><name><surname>Funk</surname><given-names>R</given-names></name></person-group><article-title>Corneal endothelial cytotoxicity of riboflavin/UVA treatment <italic>in vitro</italic></article-title><source>Ophthalmic Res</source><year>2003</year><volume>35</volume><fpage>324</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">14688422</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Nottage</surname><given-names>JM</given-names></name><name><surname>Mirchia</surname><given-names>K</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>Mohan</surname><given-names>K</given-names></name><name><surname>Nirankari</surname><given-names>VS</given-names></name></person-group><article-title>Persistent corneal edema after collagen cross-linking for keratoconus</article-title><source>Am J Ophthalmol</source><year>2012</year><volume>154</volume><fpage>922</fpage><lpage>926.e1</lpage><pub-id pub-id-type="pmid">22959362</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagga</surname><given-names>B</given-names></name><name><surname>Pahuja</surname><given-names>S</given-names></name><name><surname>Murthy</surname><given-names>S</given-names></name><name><surname>Sangwan</surname><given-names>VS</given-names></name></person-group><article-title>Endothelial failure after collagen cross-linking with riboflavin and UV-A: Case report with literature review</article-title><source>Cornea</source><year>2012</year><volume>31</volume><fpage>1197</fpage><lpage>1200</lpage><pub-id pub-id-type="pmid">22960648</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinciguerra</surname><given-names>P</given-names></name><name><surname>Camesasca</surname><given-names>FI</given-names></name><name><surname>Romano</surname><given-names>MR</given-names></name></person-group><article-title>Corneal crosslinking and lens opacity</article-title><source>Ophthalmology</source><year>2011</year><volume>118</volume><fpage>2519.e1</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">22136675</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grewal</surname><given-names>DS</given-names></name><name><surname>Brar</surname><given-names>GS</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Sood</surname><given-names>V</given-names></name><name><surname>Singla</surname><given-names>M</given-names></name><name><surname>Grewal</surname><given-names>SP</given-names></name></person-group><article-title>Corneal collagen crosslinking using riboflavin and ultraviolet-A light for keratoconus: One-year analysis using Scheimpflug imaging</article-title><source>J Cataract Refract Surg</source><year>2009</year><volume>35</volume><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">19251133</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datiles</surname><given-names>MB</given-names><suffix>3rd</suffix></name><name><surname>Magno</surname><given-names>BV</given-names></name><name><surname>Freidlin</surname><given-names>V</given-names></name></person-group><article-title>Study of nuclear cataract progression using the National Eye Institute Scheimpflug system</article-title><source>Br J Ophthalmol</source><year>1995</year><volume>79</volume><fpage>527</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">7626567</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magno</surname><given-names>BV</given-names></name><name><surname>Freidlin</surname><given-names>V</given-names></name><name><surname>Datiles</surname><given-names>MB</given-names><suffix>3rd</suffix></name></person-group><article-title>Reproducibility of the NEI Scheimpflug Cataract Imaging System</article-title><source>Invest Ophthalmol Vis Sci</source><year>1994</year><volume>35</volume><fpage>3078</fpage><lpage>3084</lpage><pub-id pub-id-type="pmid">8206726</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkwood</surname><given-names>BJ</given-names></name><name><surname>Hendicott</surname><given-names>PL</given-names></name><name><surname>Read</surname><given-names>SA</given-names></name><name><surname>Pesudovs</surname><given-names>K</given-names></name></person-group><article-title>Repeatability and validity of lens densitometry measured with Scheimpflug imaging</article-title><source>J Cataract Refract Surg</source><year>2009</year><volume>35</volume><fpage>1210</fpage><lpage>1215</lpage><pub-id pub-id-type="pmid">19545810</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polunin</surname><given-names>GS</given-names></name><name><surname>Makarova</surname><given-names>IA</given-names></name><name><surname>Bubnova</surname><given-names>IA</given-names></name></person-group><article-title>Efficacy of catalin eyed drops in age-related cataract agents</article-title><source>Vestn Oftalmol</source><year>2010</year><volume>126</volume><fpage>36</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">20645574</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wollensak</surname><given-names>G</given-names></name><name><surname>Wilsch</surname><given-names>M</given-names></name><name><surname>Spoerl</surname><given-names>E</given-names></name><name><surname>Seiler</surname><given-names>T</given-names></name></person-group><article-title>Collagen fiber diameter in the rabbit cornea after collagen crosslinking by riboflavin/UVA</article-title><source>Cornea</source><year>2004</year><volume>23</volume><fpage>503</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">15220736</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>JN</given-names></name><name><surname>Benedek</surname><given-names>GB</given-names></name><name><surname>Dohlman</surname><given-names>CH</given-names></name><name><surname>Kravitt</surname><given-names>B</given-names></name></person-group><article-title>Structural alterations affecting transparency in swollen human corneas</article-title><source>Invest Ophthalmol</source><year>1968</year><volume>7</volume><fpage>501</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">5693186</pub-id></element-citation></ref></ref-list></back></article>